These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35687107)

  • 1. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filipattos G; Ritter I; Schüler E; Kraus BJ; Pocock SJ; Anker SD; Packer M
    Eur Heart J; 2022 Aug; 43(31):2984-2993. PubMed ID: 35687107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Ferreira JP; Butler J; Zannad F; Filippatos G; Schueler E; Steubl D; Zeller C; Januzzi JL; Pocock S; Packer M; Anker SD
    J Am Coll Cardiol; 2022 Mar; 79(12):1129-1137. PubMed ID: 35331406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    Ferreira JP; Claggett BL; Liu J; Desai AS; Pfeffer MA; Anand IS; van Veldhuisen DJ; Kober L; Cleland JGF; Rouleau JL; Packer M; Zile MR; Shi VC; Lefkowitz MP; Shah SJ; Vardeny O; Zannad F; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2021 May; 23(5):776-784. PubMed ID: 33609066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum potassium in the PARADIGM-HF trial.
    Ferreira JP; Mogensen UM; Jhund PS; Desai AS; Rouleau JL; Zile MR; Rossignol P; Zannad F; Packer M; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2020 Nov; 22(11):2056-2064. PubMed ID: 32809261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Doehner W; Anker SD; Butler J; Zannad F; Filippatos G; Ferreira JP; Salsali A; Kaempfer C; Brueckmann M; Pocock SJ; Januzzi JL; Packer M
    Eur Heart J; 2022 Sep; 43(36):3435-3446. PubMed ID: 35788657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
    Clephas PRD; Radhoe SP; Linssen GCM; Langerveld J; Plomp J; Smits JPP; Nagelsmit MJ; Rocca HB; Brugts JJ
    ESC Heart Fail; 2023 Apr; 10(2):1481-1487. PubMed ID: 36738129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.
    Coats AJS; Butler J; Tsutsui H; Doehner W; Filippatos G; Ferreira JP; Böhm M; Chopra VK; Verma S; Nordaby M; Iwata T; Nitta D; Ponikowski P; Zannad F; Packer M; Anker SD
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):412-424. PubMed ID: 38158636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J; Usman MS; Filippatos G; Ferreira JP; Böhm M; Brueckmann M; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Senni M; Sumin M; Verma S; Zaremba-Pechmann L; Pocock SJ; Packer M; Anker S
    JAMA Cardiol; 2023 Jul; 8(7):640-649. PubMed ID: 37223933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
    Monzo L; Ferreira JP; Cleland JGF; Pellicori P; Mariottoni B; Verdonschot JAJ; Hazebroek MR; Collier TJ; Cuthbert JJ; Pieske B; Edelmann F; Petutschnigg J; Khan J; Ahmed FZ; Girerd N; Bozec E; Díez J; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Rossignol P; Zannad F
    ESC Heart Fail; 2022 Dec; 9(6):4352-4357. PubMed ID: 36065795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
    Ferreira JP; Konstam M; Rossignol P; Kiernan MS; Zannad F
    J Card Fail; 2023 Jan; 29(1):45-52. PubMed ID: 36244652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
    Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis.
    Ferreira JP; Zannad F; Packer M; Filippatos G; Pocock SJ; Vasques-Nóvoa F; Böhm M; Butler J; Anker S
    Eur J Heart Fail; 2024 Apr; 26(4):952-959. PubMed ID: 38439585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.
    Anker SD; Butler J; Usman MS; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Rocca HPB; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; González-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Iwata T; Schnee JM; Brueckmann M; Pocock SJ; Zannad F
    Nat Med; 2022 Dec; 28(12):2512-2520. PubMed ID: 36471037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.
    Rastogi T; Ferreira JP; Butler J; Kraus BJ; Mattheus M; Brueckmann M; Filippatos G; Wanner C; Pocock SJ; Packer M; Anker SD; Zannad F
    Eur J Heart Fail; 2024 Apr; 26(4):885-896. PubMed ID: 38247160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.